{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:05:12Z","timestamp":1768349112693,"version":"3.49.0"},"reference-count":69,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T00:00:00Z","timestamp":1543795200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1007\/s40263-018-0588-3","type":"journal-article","created":{"date-parts":[[2018,12,3]],"date-time":"2018-12-03T10:10:46Z","timestamp":1543831846000},"page":"1-8","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9219-2083","authenticated-orcid":false,"given":"A. George","family":"Awad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,3]]},"reference":[{"key":"588_CR1","first-page":"3","volume-title":"Beyond assessment of quality of life in schizophrenia","author":"MV Seeman","year":"2016","unstructured":"Seeman MV. Schizophrenia and its sequelae. In: Awad AG, Voruganti LNP, editors. Beyond assessment of quality of life in schizophrenia. Switzerland: Springer International Publishing; 2016. p. 3\u201313."},{"key":"588_CR2","doi-asserted-by":"publisher","first-page":"8","DOI":"10.2165\/00023210-199504010-00002","volume":"4","author":"AG Awad","year":"1995","unstructured":"Awad AG, Voruganti LNP, Heselgrave RJ. The aim of antipsychotic medications: what are they and are they being achieved? CNS Drugs. 1995;4:8\u201316.","journal-title":"CNS Drugs"},{"key":"588_CR3","first-page":"191","volume":"37","author":"MM Singh","year":"1976","unstructured":"Singh MM, Smith JM. Dysphoric response to neuroleptic treatment in schizophrenia and its prognostic significance. Dis Nerv Syst. 1976;37:191\u20137.","journal-title":"Dis Nerv Syst."},{"key":"588_CR4","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1001\/archpsyc.1981.01780270073010","volume":"38","author":"T Putten Van","year":"1981","unstructured":"Van Putten T, May PRA, Marader S, Wittman LA. Subjective response to antipsychotic drugs. Arch Gen Psychiatry. 1981;38:187\u201390.","journal-title":"Arch Gen Psychiatry"},{"key":"588_CR5","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1001\/archpsyc.1978.01770330075006","volume":"15","author":"T Putten Van","year":"1978","unstructured":"Van Putten T, May PRA. \u201cAkinetic depression\u201d in schizophrenia. Arch Gen Psychiatry. 1978;15:1101\u20137.","journal-title":"Arch Gen Psychiatry"},{"key":"588_CR6","first-page":"13","volume":"48","author":"T Putten Van","year":"1987","unstructured":"Van Putten T, Marder SR. Behavioural toxicity of antipsychotic drugs. J Clin Psychiatry. 1987;48:13\u20139.","journal-title":"J Clin Psychiatry"},{"key":"588_CR7","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1176\/ajp.136.9.1216","volume":"136","author":"ED Caine","year":"1979","unstructured":"Caine ED, Polensky RJ. Haloperidol induced dysphoria in patients with Tourette\u2019s syndrome. Am J Psychiatry. 1979;136:1216\u20137.","journal-title":"Am J Psychiatry"},{"key":"588_CR8","doi-asserted-by":"crossref","unstructured":"Van Putten, T. Mutalipassi LR, Malkin MD. Phenothiazine induced decompensation. Arch Gen Psychiatry. 1974;30:102\u2013105.","DOI":"10.1001\/archpsyc.1974.01760070080012"},{"key":"588_CR9","first-page":"130","volume-title":"From psychopharmacology to neuropsychopharmacology in the 1980s and the story of CINP as told in autobiography","author":"AG Awad","year":"2002","unstructured":"Awad AG. The psychology of medication-taking: the development of a research program in psychopharmacology. In: Ban TA, Healy D, Shorter E, editors. From psychopharmacology to neuropsychopharmacology in the 1980s and the story of CINP as told in autobiography. Budapest: Animula Publishing House; 2002. p. 130\u20134."},{"key":"588_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1177\/070674378302800407","volume":"28","author":"TP Hogan","year":"1983","unstructured":"Hogan TP, Awad AG. Pharmacotherapy and suicide risk in schizophrenia. Can J Psychiatry. 1983;28:277\u201381.","journal-title":"Can J Psychiatry"},{"key":"588_CR11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1017\/S0033291700050182","volume":"13","author":"TP Hogan","year":"1983","unstructured":"Hogan TP, Awad AG, Eastwood MR. A self-report scale, predictive of drug compliance in schizophrenia: reliability and discriminative ability. Psychol Med. 1983;13:177\u201383.","journal-title":"Psychol Med"},{"key":"588_CR12","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/070674378503000405","volume":"30","author":"TP Hogan","year":"1985","unstructured":"Hogan TP, Awad AG, Eastwood MR. Early subjective response and prediction of outcome to neuroleptic therapy in schizophrenia. Can J Psychiatry. 1985;30:246\u20138.","journal-title":"Can J Psychiatry"},{"key":"588_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/0278-5846(85)90021-1","volume":"9","author":"AG Awad","year":"1985","unstructured":"Awad AG, Hogan TP. Early treatment and prediction of response to neuroleptics in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 1985;9:585\u20138.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry."},{"key":"588_CR14","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1093\/schbul\/19.3.609","volume":"19","author":"AG Awad","year":"1993","unstructured":"Awad AG. Subjective response to neuroleptics in schizophrenia. Schizophr Bulletin. 1993;19:609\u201317.","journal-title":"Schizophr Bulletin."},{"key":"588_CR15","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1111\/j.1600-0447.2004.00478.x","volume":"111","author":"D Naber","year":"2005","unstructured":"Naber D. Subjective effects of antipsychotic treatment (editorial). Acta Psychiatr Scand. 2005;111:81\u20133.","journal-title":"Acta Psychiatr Scand"},{"key":"588_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.schres.2006.07.012","volume":"88","author":"LNP Voruganti","year":"2006","unstructured":"Voruganti LNP, Awad AG. Subjective and behavioural consequences of striatal dopmaine depletion in schizophrenia: findings from in vivo SPECT study. Schiz Res. 2006;88:179\u201388.","journal-title":"Schiz Res."},{"key":"588_CR17","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1093\/schbul\/16.1.31","volume":"16","author":"KT Mueser","year":"1990","unstructured":"Mueser KT, Yarnold PR, Levinson DF. Prevalence of substance abuse in schizophrenia: demographics and clinical correlates. Schizophr Bull. 1990;16:31\u201354.","journal-title":"Schizophr Bull"},{"key":"588_CR18","first-page":"3511","volume":"264","author":"DA Reigier","year":"1990","unstructured":"Reigier DA, Famer ME, Rae DS. Comorbidity of mental disorders with alcohol and other drugs of abuse. JAMA. 1990;264:3511\u20138.","journal-title":"JAMA"},{"key":"588_CR19","doi-asserted-by":"crossref","unstructured":"Cleary TA, Linn RL. Variability of Kuder-Richardson variability estimates. Princeton: Educational Testing Services, Formula\u00a020; 1968.","DOI":"10.1002\/j.2333-8504.1968.tb00158.x"},{"key":"588_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/BF02289743","volume":"30","author":"HF Kaiser","year":"1965","unstructured":"Kaiser HF, Caffrey J. Alpha factor analysis. Psychometrics. 1965;30:1\u201314.","journal-title":"Psychometrics."},{"key":"588_CR21","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.euroneuro.2012.02.008","volume":"10","author":"RE Nielsen","year":"2012","unstructured":"Nielsen RE, Lindstrom E, Nielsen J, Levander S. DAI-10 is as good as DAI-30 in schizophrenia. Eur Neuropsychopharmacol. 2012;10:747\u201350.","journal-title":"Eur Neuropsychopharmacol"},{"key":"588_CR22","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1093\/schbul\/20.2.297","volume":"20","author":"PJ Wieden","year":"1994","unstructured":"Wieden PJ, Rapkin B, Mott T, Zygmunt A, Goldman D, Horvitz-Lennon M, Frances A. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull. 1994;20:297\u2013310.","journal-title":"Schizophr Bull"},{"key":"588_CR23","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/978-3-7091-6636-9_10","volume-title":"Prediction of Neuroleptic treatment outcome in schizophrenia\u2014concepts and methods","author":"D Naber","year":"1994","unstructured":"Naber D, Walther A, Kircher T, Hayek D, Holzbach R. Subjective effects of neuroleptics predict compliance. In: Gaebel W, Awad AG, editors. Prediction of Neuroleptic treatment outcome in schizophrenia\u2014concepts and methods. Wien: Springer; 1994. p. 85\u201398."},{"key":"588_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/S0920-9964(01)00161-X","volume":"56","author":"LNP Voruganti","year":"2002","unstructured":"Voruganti LNP, Awad AG. Personal evaluation of transitions in treatment (PETiT): a scal to measure subjective tolerability of antipsychotic medications. Schizophr Res. 2002;56:37\u201346.","journal-title":"Schizophr Res"},{"key":"588_CR25","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.schres.2013.03.008","volume":"147","author":"K Baumstrack","year":"2013","unstructured":"Baumstrack K, Boyer L, Boucekine M, Aghababian V, Parola N, Lancon C, Auquier P. Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment. Schizophr Res. 2013;147:58\u201367.","journal-title":"Schizophr Res"},{"key":"588_CR26","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2165\/11594470-000000000-00000","volume":"30","author":"AG Awad","year":"2012","unstructured":"Awad AG, Voruganti LNP. Measuring quality of life in patients with schizophrenia\u2014an update. Pharmacoeconomics. 2012;30:183\u201395.","journal-title":"Pharmacoeconomics."},{"key":"588_CR27","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.schres.2006.11.011","volume":"90","author":"N Niv","year":"2007","unstructured":"Niv N, Cohen AN, Mintz J, Ventura J, Young AS. The validity of using patient self-report to assess psychotic symptoms in schizophrenia. Schizophr Res. 2007;90:245\u201350.","journal-title":"Schizophr Res"},{"key":"588_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.schres.2006.12.017","volume":"91","author":"PM Wehmeier","year":"2007","unstructured":"Wehmeier PM, Kluge M, Schact A. Correlation of physician and patient-related quality of life during antipsychotic treatment in outpatients with schizophrenia. Schizophr Res. 2007;91:178\u201386.","journal-title":"Schizophr Res"},{"key":"588_CR29","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s00127-004-0761-5","volume":"39","author":"A Becchi","year":"2004","unstructured":"Becchi A, Rucci P, Placentino A, Neri G, de Girolamo G. Quality of life in patients with schizophrenia\u2014comparison of self-reports and proxy assessments. Soc Psychiat and Psychiatr Epidemiol. 2004;39:397\u2013401.","journal-title":"Soc Psychiat and Psychiatr Epidemiol."},{"key":"588_CR30","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1097\/01.nmd.000126702.30745.1d","volume":"192","author":"F Lirand","year":"2004","unstructured":"Lirand F, Droulout T, Parrot N, Verdoux H. Agreement between self-rated and clinically assessed symptoms in subjects with psychosis. J Nerv Ment Dis. 2004;192:352\u20136.","journal-title":"J Nerv Ment Dis."},{"key":"588_CR31","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-3-642-57392-7_3","volume-title":"Zukunfts Perspectives in psychiatries and psychotherapie","author":"AG Awad","year":"2002","unstructured":"Awad AG, Voruganti LNP. The subjective\/objective dichotomy: relevance to nosology, research and management. In: Gaebel W, editor. Zukunfts Perspectives in psychiatries and psychotherapie. Darmstadt: Steinkopff; 2002. p. 21\u20137."},{"key":"588_CR32","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1017\/S0033291797005874","volume":"28","author":"LNP Voruganti","year":"1998","unstructured":"Voruganti LNP, Heselgrave RS, Awad AG, Seeman M. Quality of life measurement in schizophrenia; reconciling the question of subjectivity with the quest of reliability. Psychol Med. 1998;28:165\u201372.","journal-title":"Psychol Med"},{"key":"588_CR33","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s00213-003-1648-y","volume":"171","author":"LNP Voruganti","year":"2004","unstructured":"Voruganti LNP, Awad AG. Neuroleptic dysphoria: towards a new synthesis. Psychopharmacology. 2004;171:121\u201332.","journal-title":"Psychopharmacology"},{"key":"588_CR34","first-page":"427","volume":"55","author":"PH Delespaul","year":"2013","unstructured":"Delespaul PH. Consensus regarding the definition of persons with severe mental illness and the number of such persons in the Netherlands. Tijdschr Psychiatr. 2013;55:427\u201338.","journal-title":"Tijdschr Psychiatr"},{"issue":"Suppl 3","key":"588_CR35","first-page":"123","volume":"10","author":"AG Awad","year":"1995","unstructured":"Awad AG, Hogan TP, Voruganti LNP, Heselgrave RJ. Patient subjective experiences on antipsychotic medication; implications for outcome and quality of life. Int Clin Psychopharmacol. 1995;10(Suppl 3):123\u201332.","journal-title":"Int Clin Psychopharmacol"},{"key":"588_CR36","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1177\/070674378903400716","volume":"34","author":"AG Awad","year":"1989","unstructured":"Awad AG. Drug therapy in schizophrenia\u2014variability of the outcome and prediction of response. Can J Psychiatry. 1989;34:711\u201320.","journal-title":"Can J Psychiatry"},{"key":"588_CR37","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0893-133X(97)00043-2","volume":"17","author":"M Laruelle","year":"1997","unstructured":"Laruelle M, D\u2019Souza CD, Baldwin RM, Abi-Dergham A, Kanes SJ, Fingado CL, et al. Imaging D2 receptor occupancy by endogenous dopamine in humans. Neuropsychopharmacology. 1997;17:162\u201374.","journal-title":"Neuropsychopharmacology."},{"key":"588_CR38","unstructured":"Laruelle M. Abi-Dargham A, von Dyck CH, Rosenblatt W, Zia-Ponce Y, Zoghbi SS et al. SPECT imaging of striatal dopamine release after amphetamine challenge. J Nucl Med. 1995;36:1182\u20131190."},{"key":"588_CR39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/978-1-4020-5779-3_2","volume-title":"Quality of life impairment in schizophrenia, mood and anxiety disorders","author":"LNP Voruganti","year":"2007","unstructured":"Voruganti LNP, Awad AG. Role of dopmaine in pleasure, reward and subjective responses as important aspects of quality of life. In: Ritsner M, Awad AG, editors. Quality of life impairment in schizophrenia, mood and anxiety disorders. Dordrecht: Springer; 2007. p. 21\u201331."},{"key":"588_CR40","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S0893-133X(01)00263-9","volume":"25","author":"LNP Voruganti","year":"2001","unstructured":"Voruganti LNP, Slomka P, Zabel P, Costa G, So A, Mattar A, et al. The correlation between D2 binding ratio and dysphoric responses. Neuropsychopharmacol. 2001;25:642\u201350.","journal-title":"Neuropsychopharmacol."},{"key":"588_CR41","volume-title":"Manual for the profile of mood states","author":"DM McNair","year":"1992","unstructured":"McNair DM, Lorr M, Droppleman L. Manual for the profile of mood states. San Diego: Educational and Industrial Testing Services; 1992."},{"key":"588_CR42","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1097\/00005053-196509000-00006","volume":"141","author":"CA Haertzen","year":"1965","unstructured":"Haertzen CA. Addiction Research Centre Inventory (ARCI): development of a general drug estimation scale. J Ner Ment Dis. 1965;141:300\u20137.","journal-title":"J Ner Ment Dis."},{"key":"588_CR43","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"S Kay","year":"1987","unstructured":"Kay S, Fiszbein A, Opler L. The positive and negative syndrome scale for schizophrenia. Schizophr Bull. 1987;13:261\u20137.","journal-title":"Schizophr Bull"},{"key":"588_CR44","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1192\/bjp.154.5.672","volume":"154","author":"TRE Barnes","year":"1989","unstructured":"Barnes TRE. A rating scale for drug-induced akathesia. Br J Psychiatry. 1989;154:672\u20136.","journal-title":"Br J Psychiatry."},{"key":"588_CR45","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"G Simpson","year":"1970","unstructured":"Simpson G, Angus J. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11\u20139.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"588_CR46","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1176\/appi.ajp.157.6.1019","volume":"157","author":"L Haan de","year":"2000","unstructured":"de Haan L, Lavalaye J, Linszen D, Dingemans PMJ, Booij J. Subjective experiences and striatal dopamine D2 receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. Am J Psychiatry. 2000;157:1019\u201320.","journal-title":"Am J Psychiatry"},{"key":"588_CR47","first-page":"303","volume":"160","author":"L Haan de","year":"2003","unstructured":"de Haan L, Van Pruggen M, Lavalaye J, Booij J, et al. Subjective experiences and D2 receptor occupany in patients with recent-onset schizophrenia treated with low dose olanzapine or haloperidal: a randomized double blind study. J Psychiatry. 2003;160:303\u20139.","journal-title":"J Psychiatry."},{"key":"588_CR48","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1017\/S1461145709000327","volume":"5","author":"R Mizrahi","year":"2009","unstructured":"Mizrahi R, Mamo D, Rusjan P, Graff A, et al. The relationship between subjective well-being and dopamine D2 in patients treated with dopamine partial agonist and antagonist antipsychotics. Int J neuropsychopharmacology. 2009;5:715\u201321.","journal-title":"Int J neuropsychopharmacology."},{"key":"588_CR49","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.4088\/JCP.09m05466yel","volume":"10","author":"J Lafaster","year":"2011","unstructured":"Lafaster J, Van Os J, de Haan L, Thewissen V, et al. Emotional experience and estimates of D2 receptor occupancy in psychotic patients treated with haloperidol, risperidone or olanzapine: an experience sampling study. J Clin Psychiatry. 2011;10:1397\u2013404.","journal-title":"J Clin Psychiatry"},{"key":"588_CR50","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1177\/2045125315583820","volume":"5","author":"AG Awad","year":"2015","unstructured":"Awad AG, Vorguanti LNP. Revisiting the self-medication hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behaviour. Ther Adv Psychopharmacol. 2015;5:172\u20138.","journal-title":"Ther Adv Psychopharmacol."},{"key":"588_CR51","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1001\/archpsyc.1978.01770280087009","volume":"35","author":"T Putten Van","year":"1978","unstructured":"Van Putten T. Subjective response as a predictor of outcome in pharmacotherapy. Arch Gen Psychaitry. 1978;35:477\u201380.","journal-title":"Arch Gen Psychaitry."},{"key":"588_CR52","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/S0920-9964(97)82589-3","volume":"24","author":"CR Blyerler","year":"1997","unstructured":"Blyerler CR, Fenton WS. Satisfaction with treatment outcome and non-compliance in schizophrenia. Schizophr Res. 1997;24:205.","journal-title":"Schizophr Res"},{"key":"588_CR53","doi-asserted-by":"publisher","first-page":"75080","DOI":"10.1097\/00001504-200403000-00002","volume":"17","author":"AG Awad","year":"2004","unstructured":"Awad AG. Antipsychotic medications; compliance and attitudes towards treatment. Curr Opin Psychiatry. 2004;17:75080.","journal-title":"Curr Opin Psychiatry."},{"key":"588_CR54","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1177\/070674370404900504","volume":"49","author":"AG Awad","year":"2004","unstructured":"Awad AG, Voruganti LNP. New antipsychotics, compliance, quality of life and subjective tolerability\u2014are patients better off? Can J Psychiatry. 2004;49:297\u2013302.","journal-title":"Can J Psychiatry"},{"key":"588_CR55","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1471-244X-1-7","volume":"1","author":"I Garcia-Cabeza","year":"2001","unstructured":"Garcia-Cabeza I, Gomez JC. Subjective response to antipsychotic treatment and compliance in schizophrenia? A naturalistic study comparing olanzapine, risperidone and haloperidal (EFESO study). BMC Psychiatry. 2001;1:7.","journal-title":"BMC Psychiatry."},{"key":"588_CR56","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1055\/s-2008-1076729","volume":"41","author":"L Haan de","year":"2008","unstructured":"de Haan L, von Nimwegin Van, Amelsvoort T, Linszen DH, et al. Improvement of subjective well-being and enduring symptomatic remission, a 5\u00a0year follow-up of first episode schizophrenia. Pharmacopyshciatry. 2008;41:125\u20138.","journal-title":"Pharmacopyshciatry."},{"key":"588_CR57","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1055\/s-0029-1234105","volume":"42","author":"M Lambert","year":"2009","unstructured":"Lambert M, Schimmelmann BG, Naber D, Karow A, et al. Early and delayed antipsychotic response and prediction of outcome in 528 severely imparied patients with schizophrenia treated with amisulpride. Pharmacopsychiatry. 2009;42:277\u201383.","journal-title":"Pharmacopsychiatry."},{"key":"588_CR58","doi-asserted-by":"publisher","first-page":"S391","DOI":"10.1016\/S0924-977X(01)00110-9","volume":"11","author":"D Naber","year":"2001","unstructured":"Naber D, Karow A. Good tolerability equal good results: the patient\u2019s perspective. Eur Neuropsychopharmacol. 2001;11:S391\u20135.","journal-title":"Eur Neuropsychopharmacol"},{"key":"588_CR59","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.euroneuro.2010.02.001","volume":"20","author":"W Gaebel","year":"2010","unstructured":"Gaebel W, Riesbeck M, von Wilmsdorf M, Burns T, et al. Drug attitude as predictor for effectiveness in first-episode schizophrenia: results of an open randomized trial (EUFEST). Eur Neuropsychopharmacol. 2010;20:310\u20136.","journal-title":"Eur Neuropsychopharmacol"},{"key":"588_CR60","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1176\/ajp.142.11.1259","volume":"142","author":"EJ Khantzian","year":"1985","unstructured":"Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry. 1985;142:1259\u201364.","journal-title":"Am J Psychiatry"},{"key":"588_CR61","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1097\/00005053-199707000-00008","volume":"185","author":"LNP Voruganti","year":"1997","unstructured":"Voruganti LNP, Heselgrave RJ, Awad AG. Neuroleptic dysphoria may be the missing link between schizophrenia and substance abuse. J Ner Ment Dis. 1997;185:463\u20135.","journal-title":"J Ner Ment Dis."},{"key":"588_CR62","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1038\/mp.2012.109","volume":"18","author":"J Thompson","year":"2013","unstructured":"Thompson J, Urban N, Slifstein M, Xu X, et al. Striatal dopmaine release in schizophrenia comorbid with substance dependence. Mol Psychiatry. 2013;18:909\u201315.","journal-title":"Mol Psychiatry."},{"key":"588_CR63","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.biopsych.2014.04.017","volume":"76","author":"P Trifilieff","year":"2014","unstructured":"Trifilieff P, Martinez D. Blunted dopamine release as a biomarker for vulnerability for substance use disorders. Biol Psychiatry. 2014;76:4\u20135.","journal-title":"Biol Psychiatry"},{"key":"588_CR64","doi-asserted-by":"crossref","unstructured":"Awad AG. The neurobiology of comorbid drug abuse in schizophrenia and psychotic disorders. In: Preedy V (ed). Neuropathology of drug addictions and substance misuse. Volume I. Elsevier Inc.; 2016. pp. 82\u201388.","DOI":"10.1016\/B978-0-12-800213-1.00008-0"},{"key":"588_CR65","first-page":"6","volume":"52","author":"A-N Samaha","year":"2014","unstructured":"Samaha A-N. Can antipsychotic treatment contribute to drug addiction in schizophrenia. Prog Neuropsychopharmacal Biol Psychiatry. 2014;52:6\u201316.","journal-title":"Prog Neuropsychopharmacal Biol Psychiatry."},{"key":"588_CR66","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1177\/0269881111430747","volume":"26","author":"AG Awad","year":"2012","unstructured":"Awad AG. Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development. J Psychopharmacology. 2012;26:953\u20137.","journal-title":"J Psychopharmacology."},{"key":"588_CR67","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1007\/s40263-013-0070-1","volume":"27","author":"AG Awad","year":"2013","unstructured":"Awad AG, Voruganti LNP. The impact of newer atypical antipsychotics on patient-reported outcomes in schizophrenia. CNS Drugs. 2013;27:725\u201336.","journal-title":"CNS Drugs"},{"key":"588_CR68","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1300\/J374v01n02_06","volume":"1","author":"AG Awad","year":"2005","unstructured":"Awad AG, Voruganti LNP. Neuroleptic dysphoria, comorbid drug abuse in schizophrenia and the emerging science of subjective tolerability\u2014towards a new synthesis. J Dual Diagnosis. 2005;1:83\u201393.","journal-title":"J Dual Diagnosis."},{"key":"588_CR69","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1586\/erp.10.2","volume":"10","author":"AG Awad","year":"2010","unstructured":"Awad AG. Subjective tolerability of antipsychotic medications and the emerging science of subjective tolerability disorders. Expert Rev Pharmacoecon Outcomes Res. 2010;10:1\u20134.","journal-title":"Expert Rev Pharmacoecon Outcomes Res."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-018-0588-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0588-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-018-0588-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,2]],"date-time":"2019-12-02T19:24:34Z","timestamp":1575314674000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-018-0588-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,3]]},"references-count":69,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["588"],"URL":"https:\/\/doi.org\/10.1007\/s40263-018-0588-3","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,3]]},"assertion":[{"value":"3 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A. George Awad has no conflicts of interests relevant to the content of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}